Dupixent® (dupilumab) – New indication
June 26, 2019 - The FDA announced the approval of Regeneron and Sanofi’s Dupixent (dupilumab), as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).
Download PDF
